ERBB2 and breast cancer: In this context, it is important to determine the differences in the characteristics of immune cells (e.g. CD8-positive TILs) prior to and after NAC with trastuzumab and to advance the evaluation of PD-L1 expression, with the objective to optimise the use of immune checkpoint inhibitors in the treatment of HER2-positive breast cancer.